Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 20261Lancement,...
-
GREELEY, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- JBS reported net revenue of US$21.6 billion in 1Q26, an increase of 11% compared to 1Q25. Net income totaled US$221 million from January through...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and...
-
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
-
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of...
-
Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for...
-
IRVINE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Habit just took its love of ranch to a whole new level by creating an entire destination dedicated to it. Introducing Habit Ranch, a western town...
-
Miami, FL, May 12, 2026 (GLOBE NEWSWIRE) -- Virgin Voyages, the award-winning, kid-free cruise line, recently set sail with more than 1,100 TikTok creators for a three-night voyage to the Bahamas,...
-
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability...
-
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional...